Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Global equity in the shadow of US pricing reform: Access by bargaining power? | Insights from a WHS side event
22 October 2026
At this year’s World Health Summit, OHE brought together an expert panel to discuss the impact of MFN on the global healthcare landscape and strategies to protect sustainable innovation.
The economic and health impact of UK CEiRSI: the UK Centre of Excellence for In-Silico Regulatory Science and Innovation
21 October 2026
Investing in the UK Centre of Excellence for in-silico Regulatory Science & Innovation (CEiRSI) could accelerate the adoption of in-silico technologies in the UK. Doing so could improve patient access to innovation, reduce NHS costs and strengthen the UK’s position as a global leader in in- silico technology and life sciences.
Immunoglobulin sustainability in the United Kingdom
8 October 2026
Our report, commissioned and funded by argenx, looks at the challenges to Ig sustainability and assesses four potential policy responses.
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
Biologic medicines account for over 40% of global pharmaceutical spend. When originator patents expire, biosimilar competition should drive prices down, generating cost-savings, broadening access, and improving…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical revenues might affect R&D incentives, but the Congressional Budget Office’s (CBO) revised simulation model of new drug development remains too simplified and insufficiently validated to guide real-world decisions.
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
Rare diseases may affect only a small number of people, but together they impact an estimated 300–400 million people worldwide — and only around 5% have an approved treatment. As global attention grows, including the WHO’s upcoming 10-year Global Action Plan, it is important to understand how regulation, HTA, and pricing policies across the UK, EU, and US influence the development of orphan medicines and access for patients.
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.
Taking STRIDES: The value of diagnostics against AMR
10 June 2025
Addressing a critical gap in AMR policy and evaluation Antimicrobial resistance (AMR) is a global health crisis, projected to cause up to 10 million deaths annually…